The SYK inhibitors used in all experiments were fostamatinib disodium (MedChemExpress, (Monmouth Junction, NJ, USA)), entospletinib (MedChemExpress, (Monmouth Junction, NJ, USA)), cerdulatinib (Selleckchem, Houston, TX, USA), TAK-659 (Selleckchem, Houston, TX, USA), and RO9021 (Selleckchem, Houston, TX, USA), and their main pharmacological properties are listed in Table 4 . A stock solution was prepared according to the manufacturer’s instructions before being aliquoted in RPMI-1640 or StemSpan SFEMTM medium (Stem Cell Technologies, Vancouver, BC, Canada) and being stored at −80 °C. Aliquots were thawed only once before being used in experiments.
StemSpan SFEMTM medium (Stemcell Technologies, Vancouver, BC, Canada) supplemented with exogenous G-CSF, stem cell factor (SCF), and FLT3 ligand (FLT3-L) (all from Peprotech, London, UK) was used as a cell culture medium in all experiments. Cytokines were used at a final concentration of 20 ng/mL.
StemSpan SFEMTM medium (Stemcell Technologies, Vancouver, BC, Canada) supplemented with exogenous G-CSF, stem cell factor (SCF), and FLT3 ligand (FLT3-L) (all from Peprotech, London, UK) was used as a cell culture medium in all experiments. Cytokines were used at a final concentration of 20 ng/mL.